Immuno-Oncology Translation Network: Data Management and Resource-Sharing Center at RPCI

免疫肿瘤学翻译网络：RPCI 的数据管理和资源共享中心

• 批准号: 10175779
• 负责人: Alan David Hutson
• 金额: $ 84.1万
• 依托单位: ROSWELL PARK CANCER INSTITUTE CORP
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-01 至 2021-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10175779
• 关键词: Address; Atlas of Cancer Mortality in the United States; Awareness; Bioconductor; Bioinformatics; Biometry; Biostatistics Shared Resource; Buffaloes; Cancer Center Support Grant; Catalogs; Clinical; Collaborations; Combined Modality Therapy; Communication; Communities; Comprehension; Comprehensive Cancer Center; Computer software; Computing Methodologies; Data; Data Analyses; Data Analytics; Data Management Resources; Databases; Dependence; Development; Drug Kinetics; Drug resistance; Education and Outreach; Ensure; Fostering; Funding; Goals; Hand; Immunooncology; Immunotherapy; Informatics; Information Technology; Infrastructure; Intranet; Logistics; Malignant Neoplasms; Manuscripts; Methods; Multiomic Data; Oncology; Performance; Policies; Positioning Attribute; Preparation; Principal Investigator; Procedures; Productivity; PubMed; Records; Reproducibility; Research; Research Design; Research Personnel; Research Project Grants; Resistance; Resource Sharing; Resources; Supercomputing; System; Text; Training and Education; Translations; United States National Institutes of Health; Universities; anti-cancer therapeutic; biobank; bioinformatics tool; cancer therapy; combat; data harmonization; data integration; data management; data sharing; data tools; data warehouse; design; drug sensitivity; expectation; experience; high standard; improved; innovation; interest; member; metabolomics; multidisciplinary; multiple omics; open source; operation; outreach; predictive marker; protocol development; quality assurance; real time monitoring; resistance mechanism; response; social media; structured data; support network; translational study; tumor; web portal

This application is being submitted in response to the Notice of Special Interest (NOSI) identified as NOT-CA- 20-052. Project Summary While several innovative and creative anti-cancer therapies have shown promising results, a significant expansion of their clinical use will require collaborative efforts to elucidate resistance mechanisms, exploit tumor sensitivity, map cancer dependence, discover new targets, identify predictive biomarkers, evaluate combination therapies, and develop real-time monitoring approaches. Leveraging cutting-edge multi-disciplinary team approaches, we will support the NCI Drug Resistance and Sensitivity Network (DRSN) to understand and combat mechanisms of tumor resistance and to exploit tumor sensitivity to anti-cancer therapies. Our strategy is to serve as an administration, communication, collaboration and analysis hub to coordinate the DRSN’s network-wide studies, focusing on reducing barriers to domain expertise, improving the productivity of DRSN investigators, maintaining a high standard for data harmonization and integration, designing and implementing rigorous analytical strategies, and fostering a collaborative and supportive research community. An experienced, multidisciplinary team has been assembled to pursue five Specific Aims: First, we will provide a centralized administration infrastructure to coordinate DRSN activities, building upon the Immuno-Oncology Translational Network (IOTN) Data Management and Resource-sharing Center (DMRC)’s well-functioning infrastructure that currently coordinates network studies under the umbrella of the NCI Cancer Moonshot initiative. Second, we will actively promote the DRSN and foster trans-consortium interactions, where we will leverage the IOTN DMRC’s demonstrable experience in Cross-Moonshot outreach and Bioconductor’s decades-long record in community-wide engagement. Third, we will provide multidisciplinary expertise to support DRSN collaborative research, leveraging four of the Roswell Park CCSG’s shared resources: Biostatistics, Bioinformatics, Data Bank and BioRepository, Bioanalytics, Metabolomics & Pharmacokinetics. Our analytic support will be armed with professional IT staff and informed by an experienced anti-cancer therapeutic researcher team. Fourth, we will develop innovative multi-omics data integration methods to enhance DRSN’s research capacity, capitalizing on the well-respected and highly-successful Bioconductor project. Fifth, we will disseminate resources developed in the DRSN to the broader community, unleashing the full potential of DRSN activities. Taken together, we envision our CC, in close collaboration with the DRSN components, will allow us to conduct highly effective and innovative translational studies to address the significantly unmet needs related to anti-cancer therapeutics, and fulfill the expectations and guiding principles of NCI Cancer Moonshot initiative.

该申请是为了响应特殊利益通知（NOSI）而提交 20-052。 项目摘要 虽然几种创新和创造性的反癌疗法已经显示出令人鼓舞的结果，但这是一个重要的 扩展其临床使用将需要协作努力来阐明耐药机制，利用肿瘤 敏感性，地图癌症依赖性，发现新目标，识别预测性生物标志物，评估组合 治疗并开发实时监控方法。利用尖端的多学科团队 方法，我们将支持NCI耐药性和灵敏度网络（DRSN）来理解和战斗 肿瘤耐药性的机制和利用肿瘤对抗癌疗法的敏感性。我们的策略是服务 作为政府，沟通，协作和分析中心，以协调DRSN的网络范围 研究，重点是减少领域专业知识的障碍，提高DRSN研究人员的生产率， 维持数据协调和集成，设计和实施严格的高标准 分析策略，并培养一个协作和支持性的研究社区。 一支经验丰富的多学科团队已组装，以追求五个具体目标：首先，我们将提供 基于免疫肿瘤的集中管理基础设施，以协调DRSN活动 转化网络（IOTN）数据管理和资源共享中心（DMRC）的功能良好 目前在NCI癌月光下协调网络研究的基础设施 倡议。其次，我们将积极促进DRSN和促进跨性别互动，我们将在其中 利用IOTN DMRC在跨膜片外展和生物导体方面的可证明经验 几十年来社区范围的参与记录。第三，我们将提供多学科专业知识 支持DRSN合作研究，利用Roswell Park CCSG共享的四项共享资源： 生物统计学，生物信息学，数据库和生物座席，生物分析，代谢组学和药代动力学。我们的 分析支持将由专业的IT员工武装，并通过经验丰富的反癌疗法告知 研究人员团队。第四，我们将开发创新的多摩斯数据集成方法，以增强Drsn的 研究能力，利用了备受尊敬和成功的生物导体项目。第五，我们会​​的 传播DRSN在更广泛社区中开发的资源，释放了DRSN的全部潜力 活动。综上所述，我们将与DRSN组件密切合作设想CC，将使我们 进行高效和创新的翻译研究以满足与需求相关的显着需求 进行抗癌疗法，并符合NCI癌月份倡议的期望和指导原则。